Dokumente
Suchschritt : FT=glucosamine AND FT=osteoarthritis
» Fenster schließen »

2/70 von 416 DIMDI: MEDLINE (ME60) © NLM

ND: | ME16495392
PMID: | 16495392
LR: | 20070129
CED: | 20060223
DCO: | 20060227
SEC: | ClinicalTrials.gov; NCT00032890
Autoren: | Clegg DO; Reda DJ; Harris CL; Klein MA; O'Dell JR; Hooper MM; Bradley JD; Bingham CO 3rd; Weisman MH; Jackson CG; Lane NE; Cush JJ; Moreland LW; Schumacher HR Jr; Oddis CV; Wolfe F; Molitor JA; Yocum DE; Schnitzer TJ; Furst DE; Sawitzke AD; Shi H; Brandt KD; Moskowitz RW; Williams HJ
Titel: | Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis.
Quelle: | The New England journal of medicine; VOL: 354 (8); p. 795-808 /20060223/
PM: | Print
SU: | AIM IM
Sprache: | English
CY: | United States
JID: | 0255562
ISSN: | 1533-4406
CO: | NEJMAG
Institution: | Division of Rheumatology, University of Utah School of Medicine, Salt Lake City, UT 84132, USA. gait.study@hsc.utah.edu
DT: | Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
NG: | N01AR92236 AR NIAMS
Schlagwörter
CT: | ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL/adverse effects; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL/therapeutic use; CHONDROITIN SULFATES/adverse effects; CHONDROITIN SULFATES/*therapeutic use; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLUCOSAMINE/adverse effects; GLUCOSAMINE/*therapeutic use; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE/classification; OSTEOARTHRITIS, KNEE/complications; OSTEOARTHRITIS, KNEE/*drug therapy; PAIN/classification; PAIN/*drug therapy; PAIN/etiology; PAIN MEASUREMENT; PYRAZOLES/adverse effects; PYRAZOLES/therapeutic use; SEVERITY OF ILLNESS INDEX; SULFONAMIDES/adverse effects; SULFONAMIDES/therapeutic use; TREATMENT OUTCOME
CTG: | ANTIPHLOGISTIKA, NICHTSTEROIDALE/unerwünschte Nebenwirkungen; ANTIPHLOGISTIKA, NICHTSTEROIDALE/therapeutische Anwendung; CHONDROITINSULFATE/unerwünschte Nebenwirkungen; CHONDROITINSULFATE/*therapeutische Anwendung; DOPPELBLINDMETHODE; ARZNEIMITTEL-KOMBINATIONSTHERAPIE; WEIBLICH; GLUCOSAMIN/unerwünschte Nebenwirkungen; GLUCOSAMIN/*therapeutische Anwendung; MENSCH; MÄNNLICH; MENSCHEN IM MITTLEREN LEBENSALTER; OSTEOARTHROSE, KNIE/Klassifizierung; OSTEOARTHROSE, KNIE/Komplikationen; OSTEOARTHROSE, KNIE/*Arzneimitteltherapie; SCHMERZEN/Klassifizierung; SCHMERZEN/*Arzneimitteltherapie; SCHMERZEN/Ätiologie; SCHMERZMESSUNG; PYRAZOLE/unerwünschte Nebenwirkungen; PYRAZOLE/therapeutische Anwendung; SCHWEREGRADINDEX EINER KRANKHEIT; SULFONAMIDE/unerwünschte Nebenwirkungen; SULFONAMIDE/therapeutische Anwendung; BEHANDLUNGSERGEBNIS
TE: | Anti-Inflammatory Agents, Non-Steroidal; Pyrazoles; Sulfonamides; celecoxib/169590-42-5; Glucosamine/3416-24-8; Chondroitin Sulfates/9007-28-7
CR: | 169590-42-5; 3416-24-8; 9007-28-7
NOTE: | Comment in: ACP J Club. 2006 Jul-Aug;145(1):17; Ref.PMID: 16813365; Comment in: Clin J Sport Med. 2006 Nov;16(6):528-9; Ref.PMID: 17119367; Comment in: Evid Based Med. 2006 Aug;11(4):115; Ref.PMID: 17213128; Comment in: N Engl J Med. 2006 Feb 23;354(8):858-60; Ref.PMID: 16495399; Comment in: N Engl J Med. 2006 May 18;354(20):2184-5; author reply 2184-5; Ref.PMID: 16707758; Comment in: N Engl J Med. 2006 May 18;354(20):2184-5; author reply 2184-5; Ref.PMID: 16710906; Comment in: N Engl J Med. 2006 May 18;354(20):2184-5; author reply 2184-5; Ref.PMID: 16710905
AB: | BACKGROUND: Glucosamine and chondroitin sulfate are used to treat osteoarthritis. The multicenter, double-blind, placebo- and celecoxib-controlled Glucosamine/chondroitin Arthritis Intervention Trial (GAIT) evaluated their efficacy and safety as a treatment for knee pain from osteoarthritis. METHODS: We randomly assigned 1583 patients with symptomatic knee osteoarthritis to receive 1500 mg of glucosamine daily, 1200 mg of chondroitin sulfate daily, both glucosamine and chondroitin sulfate, 200 mg of celecoxib daily, or placebo for 24 weeks. Up to 4000 mg of acetaminophen daily was allowed as rescue analgesia. Assignment was stratified according to the severity of knee pain (mild [N=1229] vs. moderate to severe [N=354]). The primary outcome measure was a 20 percent decrease in knee pain from baseline to week 24. RESULTS: The mean age of the patients was 59 years, and 64 percent were women. Overall, glucosamine and chondroitin sulfate were not significantly better than placebo in reducing knee pain by 20 percent. As compared with the rate of response to placebo (60.1 percent), the rate of response to glucosamine was 3.9 percentage points higher (P=0.30), the rate of response to chondroitin sulfate was 5.3 percentage points higher (P=0.17), and the rate of response to combined treatment was 6.5 percentage points higher (P=0.09). The rate of response in the celecoxib control group was 10.0 percentage points higher than that in the placebo control group (P=0.008). For patients with moderate-to-severe pain at baseline, the rate of response was significantly higher with combined therapy than with placebo (79.2 percent vs. 54.3 percent, P=0.002). Adverse events were mild, infrequent, and evenly distributed among the groups. CONCLUSIONS: Glucosamine and chondroitin sulfate alone or in combination did not reduce pain effectively in the overall group of patients with osteoarthritis of the knee. Exploratory analyses suggest that the combination of glucosamine and chondroitin sulfate may be effective in the subgroup of patients with moderate-to-severe knee pain. (ClinicalTrials.gov number, NCT00032890.). - CNOTE: Copyright 2006 Massachusetts Medical Society.

» Volltext »
» Fenster schließen »